Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence? K. A. NyropG. R. WilliamsS. S. Shachar Review 24 June 2016 Pages: 203 - 217
Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications Jamunarani VeeraraghavanJiacheng MaXiao-Song Wang Review 02 July 2016 Pages: 219 - 232
Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer Koung Jin SuhHan Suk RyuSeock-Ah Im Preclinical study 21 June 2016 Pages: 233 - 241
Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer Emma E. BrightKeith J. PetrieAnnette L. Stanton Preclinical study 24 June 2016 Pages: 243 - 251
Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues Marike GabrielsonFlaminia ChiesaPer Hall Preclinical study 27 June 2016 Pages: 253 - 261
GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor α activity in breast cancer cells Zi-Jian LanYunHui HuZhenmin Lei Preclinical study 29 June 2016 Pages: 263 - 276
Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1 Ming YangWendi TengQipeng Yuan Preclinical study 04 July 2016 Pages: 277 - 286
Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer M. A. AleskandaranyA. R. GreenE. A. Rakha Preclinical Study 05 July 2016 Pages: 287 - 295
Breast fine needle aspiration continues to be relevant in a large academic medical center: experience from Massachusetts General Hospital Jianyu DongAmy LyElena Brachtel Preclinical study 06 July 2016 Pages: 297 - 305
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes Vassiliki KotoulaVasilios KaravasilisGeorge Fountzilas Clinical trial 01 July 2016 Pages: 307 - 321
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 Giancarlo PruneriKathryn P. GrayMarco Colleoni Clinical trial 02 July 2016 Pages: 323 - 331
Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer Christine LeopoldAnita K. WagnerJ. Frank Wharam Epidemiology 24 June 2016 Pages: 333 - 340
Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue Hannah OhClara BodelonJonine D. Figueroa Epidemiology 24 June 2016 Pages: 341 - 350
Reproductive factors related to childbearing and mammographic breast density Lusine YaghjyanGraham A. ColditzRulla M. Tamimi Epidemiology 28 June 2016 Pages: 351 - 359
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer Mette S. van RamshorstMargriet van der Heiden-van der LooGabe S. Sonke Epidemiology 29 June 2016 Pages: 361 - 371
Axillary evaluation and lymphedema in women with ductal carcinoma in situ Ellie J. CoromilasJason D. WrightDawn L. Hershman Epidemiology 30 June 2016 Pages: 373 - 384
Impact of a prior diagnosis of DCIS on survival from invasive breast cancer Victoria SopikJavaid IqbalSteven A. Narod Epidemiology 06 July 2016 Pages: 385 - 393
Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment Rachel A. FreedmanKasisomayajula ViswanathNancy L. Keating Brief Report 23 June 2016 Pages: 395 - 405